Creo Medical has announced that data from a research paper demonstrates that the use of Speedboat Inject can lead to NHS cost savings of over £10,000 per procedure versus traditional surgery when treating both benign and malignant large non-pedunculated colorectal polyps. This is double the savings originally estimated by the company in June 2020 and a potential saving of c50% per procedure. Reduced downstream costs from lesion recurrence and reduced procedure-related complications were substant ....
26 May 2021
Cenkos: Creo Medical Group Plc -- Health economics update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: Creo Medical Group Plc -- Health economics update
Creo Medical Group Plc (CREO:LON) | 34.8 0.1 0.7% | Mkt Cap: 125.6m
- Published:
26 May 2021 -
Author:
Chris Donnellan -
Pages:
8
Creo Medical has announced that data from a research paper demonstrates that the use of Speedboat Inject can lead to NHS cost savings of over £10,000 per procedure versus traditional surgery when treating both benign and malignant large non-pedunculated colorectal polyps. This is double the savings originally estimated by the company in June 2020 and a potential saving of c50% per procedure. Reduced downstream costs from lesion recurrence and reduced procedure-related complications were substant ....